What Actually Happens If You Sell Peptides Wrong

By Peptide Ecommerce · August 10, 2026

Your research peptide business operates within federal requirements governing product marketing and distribution, and FDA enforces those requirements when violations occur (U.S. Food and Drug Administration).

FDA uses warning letters and works with the Department of Justice on injunctions, seizures, and criminal proceedings. These four forms of action explain the consequences you can face for how you market, distribute, and represent products. FDA selects actions according to the circumstances and can pursue actions concurrently (U.S. Food and Drug Administration). The FDA's enforcement actions are triggered by specific behaviors and violations of regulations governing how research peptides can be sold and marketed.

Key Facts

FDA warning letters seek voluntary correction of significant violations (U.S. Food and Drug Administration).
A consent decree of permanent injunction is an agreed resolution entered by a court (U.S. Food and Drug Administration).
Federal food and drug law includes misdemeanor offenses governed by strict liability (U.S. Department of Justice).
FDA evaluates intended use using labeling, advertising, statements, and distribution circumstances (Cornell Legal Information Institute).

TL;DR

Your response can include the reasoning and supporting information for a disagreement with FDA's concerns.
FDA assesses implemented corrective actions when deciding whether to issue a warning letter closeout letter (U.S. Food and Drug Administration).
FDA's Pink Pony Peptides warning letter requested a response within fifteen working days.

The Four Forms of FDA Enforcement

FDA enforcement proceeds through four forms of action: a warning letter, an injunction or consent decree, a seizure, or a criminal referral, and FDA selects among them according to the circumstances of each case (U.S. Food and Drug Administration). A warning letter communicates FDA's concerns and seeks voluntary correction. An injunction is a court order, and a consent decree records an agreed resolution entered by the court. A seizure places identified products into court custody. A criminal referral presents suspected offenses for prosecutorial review, including misdemeanor and felony violations.

These actions carry different consequences for your inventory, operations, finances, and personal liberty. Understanding each action helps you identify the response and corrective work appropriate to your situation.

The FDA Warning Letter

A warning letter seeks voluntary correction of significant violations (U.S. Food and Drug Administration). It is a written communication from the FDA to an organization or individual, outlining specific violations observed during inspections or investigations. For peptide sellers, website claims and distribution practices can provide evidence of drug violations; drug manufacturing operations also carry applicable manufacturing and documentation duties. For a closer look, read What the PCAC Vote Changes for Your Peptide Store: The Correct Answer.

Operator behaviors that commonly trigger warning letters include:

Making promotional statements that suggest human use or therapeutic benefits.
Failing to disclose that products are intended solely for research purposes.
Inadequate record-keeping or documentation of manufacturing processes.

When the FDA issues a warning letter, it typically outlines the specific violations and may provide a timeline for corrective actions. Your written response documents corrective steps, recurrence prevention, and supporting records. FDA evaluates the adequacy of those actions and selects further action according to the case (U.S. Food and Drug Administration). In peptide warning letters, FDA quotes website claims as evidence of intended use and cites the applicable statutory provisions. It then specifies what the company must do to come into compliance and sets a response deadline, typically 15 business days.

Your response file includes the cited marketing materials, related communications with your web developer or marketing agency, and records of corrective actions. FDA expects you to investigate the causes of violations, address related compliance problems, and prevent recurrence. Supporting records document the changes made across your marketing channels.

Injunction and Consent Decree

If violations continue after a warning letter, FDA can work with the Department of Justice to seek an injunction. An injunction is a court order restraining specified conduct. A consent decree of permanent injunction is a negotiated resolution entered by a federal court and enforceable as a court order (U.S. Food and Drug Administration).

Circumstances that can lead FDA to pursue an injunction or consent decree include:

Repeated violations of the same issues identified in previous warning letters.
Continued marketing of products with prohibited claims after receiving a warning letter.
Refusal or inability to implement corrective actions as outlined in the warning letter.

A consent decree typically requires the operator to make specific operational changes, such as implementing new quality control measures or restricting certain marketing activities. It may also include provisions for periodic reporting to ensure continued compliance. The cost of these interventions can be significant, impacting day-to-day operations and requiring substantial resources to implement.

Beyond the operational requirements, consent decrees impose real costs. Operators typically must fund independent audits, hire compliance officers, implement new labeling review processes, and in some cases pay government oversight costs directly. For small and mid-sized operators, these costs can be existential. Understanding this before receiving a warning letter is what makes warning letters worth acting on immediately.

Seizure

Federal law authorizes seizure proceedings against adulterated or misbranded drugs and drugs distributed in violation of applicable approval requirements, subject to the statute's jurisdictional conditions. For research peptide businesses, seizure typically involves products that have been marketed with improper claims or manufactured in violation of cGMP standards.

In addition to marketing claim violations, operators may face seizure if they:

Continue to distribute products across state lines after receiving warnings about compliance issues.
Fail to address manufacturing deficiencies that could affect product quality.
Engage in deceptive practices that misrepresent the intended use of their products.

In a judicial seizure, the United States files a complaint and obtains a warrant directing the U.S. Marshal to take the products into court custody. The court determines their disposition through the condemnation proceedings (U.S. Food and Drug Administration). Outcomes include destruction or authorized efforts to bring products into compliance under FDA supervision. Your business can face inventory losses, court and supervision costs, operational disruption, and reputational consequences.

Criminal Referral

A criminal referral presents suspected offenses to prosecutors for review (U.S. Department of Justice). Federal food and drug law provides for misdemeanor liability and felony charges, with the applicable offense and evidence governing the prosecution. Criminal proceedings expose responsible individuals to fines and imprisonment.

Factors that may lead to a criminal referral include:

Intentional deception in marketing or labeling practices.
The magnitude of the operation, including large-scale distribution across state lines.
Continuing violations after multiple prior warnings and interventions.
Evidence of fraud or misrepresentation to regulatory authorities.

Criminal cases can result in substantial penalties, including fines and imprisonment for responsible individuals. Operators facing criminal referrals should be aware that these cases are taken very seriously by prosecutors and often lead to severe consequences for both the business and the individuals involved.

Federal food and drug law includes misdemeanor offenses governed by strict liability. A violation committed with intent to defraud or mislead, or after a qualifying conviction becomes final, can support felony penalties under 21 U.S.C. 333(a)(2). Prior warnings, efforts to evade scrutiny, and continued unlawful shipments can contribute evidence relevant to the government's case.

What Operators Can Do at Each Stage

A response matched to the enforcement action and its specific requirements helps you address violations and work toward compliance.

At the Warning Letter Stage

When a warning letter is received, operators should:

Take it seriously as a formal notification of violations.
Conduct an internal review to identify all issues raised by the FDA.
Develop a comprehensive corrective action plan with specific steps and timelines.
Respond to the FDA within the specified timeframe, detailing the planned actions.

A timely, documented response and effective corrective work give FDA evidence to assess your progress toward compliance. FDA evaluates the adequacy and sustainability of the corrections (U.S. Food and Drug Administration).

At the Injunction Stage

Once an injunction is in place, operators have limited options but should:

Consult with legal counsel immediately to understand the implications.
Fully cooperate with the court and FDA to develop a compliance strategy.
Implement all required operational changes without delay.
Consider negotiating terms of a consent decree that are feasible for the business.

Legal counsel becomes essential at this stage to navigate the complex requirements and potential consequences.

At the Seizure Stage

If products are seized, operators can:

Contest the seizure in court if there is valid grounds to do so.
Provide evidence or testimony to support arguments against the seizure.
Work with legal counsel to develop a defense strategy.
Prepare for significant financial and operational adjustments regardless of the outcome.

Seizure cases often require substantial legal resources to contest effectively.

At the Criminal Referral Stage

Facing criminal charges is a serious matter. Operators should:

Secure experienced criminal defense attorneys immediately.
Cooperate fully with investigators while protecting their rights.
Understand that plea bargaining may be necessary given the severity of potential penalties.
Prepare for long-term consequences including personal liability and business closure.

Criminal penalties can disrupt your business through imprisonment and financial sanctions imposed on responsible individuals (Cornell Legal Information Institute).

Behaviors That Increase Enforcement Risk

Certain behaviors can increase the risk of more severe enforcement action. These include:

Continued violations after FDA notice can support further enforcement.
Continued prohibited marketing claims can preserve evidence of ongoing violations.
Continued interstate distribution of violative products can support enforcement proceedings.
Misrepresentations to regulators or customers can supply evidence of intent to defraud or mislead (Cornell Legal Information Institute).

FDA considers compliance history, the nature of the violations, and the adequacy of corrective action when selecting a response (U.S. Food and Drug Administration). Continuing violations can lead to court proceedings with substantial operational and financial consequences.

Your warning letter response and subsequent corrective work form part of the enforcement record. FDA considers the explanation and supporting information you submit when disputing its concerns (U.S. Food and Drug Administration). Its evaluation also addresses related violations and the effectiveness of changes across your operations and marketing channels.

Starting Right: How to Avoid Enforcement Action Entirely

A compliance program starts with reviewing your labeling, marketing, distribution practices, and applicable manufacturing and recordkeeping duties. Responsible officials have a legal duty to keep these activities compliant. Documented reviews and prompt corrections support that work.

Your compliance strategy centers on the products you market, the claims you make, and the distribution activities you conduct. FDA evaluates intended use from labeling, marketing, and distribution (Cornell Legal Information Institute). Federal law also permits seizure of violative drugs held for sale after interstate shipment (Cornell Legal Information Institute). Documented compliance work supports lawful ongoing operations.

Frequently Asked Questions

How is a seized shipment contested?

An interested owner or agent files a verified claim stating their interest in the seized goods. A proper claimant can then litigate the government's seizure case.

How long can a permanent injunction remain in effect?

A permanent injunction remains in effect until the court dissolves it. Its terms continue to govern your activities while the order remains in force.

What information belongs in a warning letter response when corrective work takes longer?

FDA's Pink Pony Peptides letter requested the reason for a delay and the time needed to complete correction. It also requested an explanation of recurrence prevention measures and copies of related documentation.

Sources

Considering outside help? Questions to ask before choosing a peptide business coach